You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • EP258/#917  Recurrence-free survival and overall survival in early-stage ovarian cancer considering homologous recombination deficiency(HRD) status

Article Text

Article menu

Download PDFPDF

ePoster Viewing
AS11. Ovarian cancer
EP258/#917  Recurrence-free survival and overall survival in early-stage ovarian cancer considering homologous recombination deficiency(HRD) status
Free
  1. Won-Ji Kim1,
  2. Joseph Noh2,
  3. Chel Hun Choi2,
  4. Tae-Joong Kim1,
  5. Jeong-Won Lee2,
  6. Byoung Gie Kim3 and
  7. Yoo Young Lee3
  1. 1Samsung Medical Center, Obstetrics and Gynecology, Gynecologic Cancer Center, Seoul, Korea, Republic of
  2. 2Samsung Medical Center, Obstetrics and Gynecology, Seoul, Korea, Republic of
  3. 3Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of

Abstract

Introduction We aimed to determine the recurrence rate and survival outcome among early-stage epithelial ovarian cancer cases in relationship1 to homologous recombination deficiency (HRD) status.

Methods We conducted single institution retrospective study of stage I/II EOC patients from 2008 to 2022. HRD was defined as evidence of germline or somatic BRCA mutation. Kaplan-Meier analyses were performed.

Results A total of 456 stage I/II patients were included. 22/456 (4.8%) had a germline or somatic BRCA1 mutation 46/456 (10.0%) had a BRCA2 mutation; These 68/456(14.9%) patients comprised the HRD group. The remaining cases were confirmed homologous recombination proficient (HRP, 388/456, 85.1%). The overall recurrence rate was 90/456 (19.7%). The recurrence rate was 68/388 (17.5%) in HRP group and 22/68 (32.4%) in HRD group. Median Recurrence-Free Survival (RFS) was 81 months for HRD group and 109 months for HRP group (p=0.145). Median overall survival was not reached for the HRP group and 147 months (95% CI: 129.6–158.8) for the HRD group (p=0.231), with no significant difference.

Conclusion/Implications In this early-stage cohort, despite a high rate of complete surgical staging and adjuvant chemotherapy, recurrence rate was high. The proportion of relapsed patients was higher in the HRD group than in the HRP group, but there was no statistically significant difference. There was no significant difference in RFS and OS between HRD group and HRP group.

https://doi.org/10.1136/ijgc-2023-IGCS.330

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.